Plus Therapeutics发布Reyobiq™临床项目及Cnside®美国商业化业务进展

美股速递
Jan 22

Plus Therapeutics公司近日就其核心产品Reyobiq™的临床研发计划以及Cnside®在美国市场的商业化布局,向投资者同步了最新业务动态。此次更新涵盖了临床试验的关键节点与市场推广的战略路径,展现出公司在肿瘤治疗领域的技术积累与商业化执行力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10